

## **CURRICULUM VITAE**

**Paul M. Beringer, Pharm.D.**

### **PERSONAL INFORMATION**

Business Address: University of Southern California, School of Pharmacy  
1985 Zonal Avenue, Los Angeles, California 90033

Business Telephone: (323) 442-1402

Business FAX: (323) 442-1395

Email Address: beringer@usc.edu

### **EDUCATION**

1983-86 University of California Irvine, School of Biological Sciences  
Irvine, California

1986-90 University of Southern California, School of Pharmacy,  
Los Angeles, California  
Pharm.D.

### **POSTGRADUATE EDUCATION**

1990-91 Resident in Clinical Pharmacy, University of California San Francisco,  
School of Pharmacy, San Francisco, California

1991-92 Specialty Resident in Clinical Pharmacokinetics, University of California  
San Francisco, School of Pharmacy, San Francisco, California

### **LICENSURE**

1990-Present California State Board of Pharmacy RPH 43971

### **BOARD CERTIFICATION**

1995-2002 Board Certified Pharmacotherapy Specialist BCPS 295378  
2002-2009 Recertified

## PROFESSIONAL EXPERIENCE

- 2018 – Present Professor of Clinical Pharmacy University of Southern California, School of Pharmacy, Los Angeles, California
- 2017 – Present Chair, Titus Family Department of Clinical Pharmacy
- 2001 – Present Associate Professor of Clinical Medicine, Department of Pulmonary and Critical Care Medicine, Keck School of Medicine, Los Angeles, California
- 2000 – Present Associate Professor of Clinical Pharmacy, University of Southern California, School of Pharmacy, Los Angeles, California
- 1992 - 2000 Assistant Professor of Clinical Pharmacy, University of Southern California, School of Pharmacy, Los Angeles, California
- 1992 - 2000 Coordinator, Therapeutic Drug Monitoring Service, Department of Pharmaceutical Services, USC University Hospital, Los Angeles, California

## TEACHING EXPERIENCE

### *Course Coordination*

- 2011 – Present PHRD 559 Pharmacokinetics

### *PhD Students*

- 2020- Present Eunjin Hong, Pharm.D.  
2018- 2021 Jenny Park  
CXPT Best TA Award 2019  
AFPE Predoctoral Training Award 2019 (renewed 2020)
- 2017 – Present Mansour Dughbaj  
T90 Predoctoral Training Award 2020 (renewed 2021)  
AFPE Predoctoral Training Award 2020
- 2015 - 2019 Jordanna Jayne  
Krown Fellowship Award 2018
- 2011 – 2016 Timothy Bensman, Pharm.D.  
F31 Predoctoral Training Award 2014-2016  
T90 Predoctoral Training Award 2013  
ACCP-Medco Scholarship Award 2011

### *Masters Students:*

- 2021-2022 Sun Woo Kim, University of Southern California  
2016-2017 Jenny Park, University of Southern California  
2014-2015 Hao Guo, University of Southern California

2013	Niklas Werner, Göteborg University, Sweden
2012	Liza Minnhagen, Göteborg University, Sweden
2012	Inngeborg de Veth, Utrecht University, The Netherlands
2010	Susanne Carlsson, Göteborg University, Sweden
2008	Therese Ericsson, Göteborg University, Sweden
2007	Anna Heed, Göteborg University, Sweden
2004 – 2005	Xiyun Zhang, University of Southern California
2003 – 2004	Kitty My Tu Huynh, University of Oslo
2002 – 2003	Pål Falck Sprauten, <i>University of Oslo</i>

*Visiting Scholars*

2013-2014	Elza Kimura-Grimshaw, Ph.D., Universidade Estadual de Maringá - Paraná – Brazil
2014-2015	Meiling Sun, Ph.D., College of Science, China Pharmaceutical University

*Fellows: Antimicrobial PK/PD*

2015 - 2016	Joshua Wang, Pharm.D.
2007 – 2010	Heather Owens, Pharm.D., M.S. AFPE Fellowship Training Award 2009-2010 ACCP Infectious Diseases Fellowship Award 2008-2009
2005 – 2007	Levita Hidayat, Pharm.D.
2003 – 2005	Jane Kriengkauykiat, Pharm.D.
2002 – 2003	Emily Han, Pharm.D.
2001 – 2002	Thao Nguyen, Pharm.D.
2000 - 2001	Megan Montgomery, Pharm.D.
1999 – 2000	Amir Aminimanizani, Pharm.D.

*Residents: Pharmacy Practice*

1997 – 2018	Preceptor, Pharmacy Practice Residency, University of Southern California, School of Pharmacy
-------------	---

*APPE:*

2005	Clinical Pharmacokinetics Clerkship
2000 – 2017	Acute Care Medicine Clerkship
1994 - 2000	Clinical Pharmacokinetics Clerkship
1992 - 1994	Acute Care Medicine Clerkship

**UNIVERSITY AND PUBLIC SERVICE****Health Science Campus**

2015	Member, Clinical Research Advisory Group
2010	Member, HSC Master Planning Committee
2010	Member, AAHRP Institutional Review Board Re-accreditation
2009	Member, Therapeutic Intent Committee
2007	Member, AAHRP Institutional Review Board Accreditation

2004 - 2012	Member, Institutional Review Board
2004 - 2010	Member, General Clinical Research Center (GCRC) advisory board

### USC School of Pharmacy

2019	Faculty Advisor, Rho Chi Theta chapter
2015-2016	Member, PHTS Graduate Curriculum Committee
2015-2016	Member, PHTS Graduate Admissions Committee
2015	Member, Research Advisory Committee
2015	Member, Executive Board
2015 - 2016	Member, Curriculum Committee
2011 – Present	Member, IMCC
2011	Member, Executive Committee of the Pharmacy Faculty Counsel
2006	Member, Pharmaceutical Sciences Faculty Search Committee - PK
2005	Member, Graduate Affairs Committee
2004-2005	Member, Deans Search Committee
2004-2005	Chair, Senior Translational Scientist Faculty Search Committee, Department of Pharmacy
2004	Chair, Faculty Search Committee, Department of Pharmacy
2004	Member, School of Pharmacy Strategic Planning - Research
2003	Chair, Acute Care Medicine Faculty Search Committee, Department of Pharmacy
2002	Member, Faculty Search Committee, Pharmaceutical Sciences
2001	Member, Faculty Search Committee, USCUH Pharmacy Director
2001	Chair, Task Force on Post-Pharm.D. USC Training Programs
2001	Chair, Promotion Subcommittee
2000	Chair, Task Force on USC Clinical Fellowship Guidelines
2000	Member, Search committee – USCUH Faculty Position
2000	Member, Ad-hoc Task force on Clinical Faculty Profiles
1999 – Present	Member, Residency Council
1999	Member, Ad-hoc Faculty Search Committee-USCUH.
1999 - Present	Member, Ad-hoc Faculty Retention Committee.
1998 - 2000	Member, Executive Committee of the Pharmacy Faculty Assembly
1998 - 1999	Publicity Subcommittee, USC/Japan Conference on “Frontiers of Drug Development”
1996 – 1997	Member, Ad-Hoc Search Committee-LAC/USC Faculty Position
1996 - Present	Faculty Development Ad-hoc Committee
1995 – 1996	Peer Review Committee
1995	Curriculum Revision Consultant, Pharmaceutics Course

### Professional Societies

1997 - Present	American Association of Colleges of Pharmacy (AACP)
1996 - Present	Southern California College of Clinical Pharmacy (SCCCP) Chair, Continuing Education Committee (1996-97) President Elect (1998)

	President (1999)
	Immediate Past President (2000)
1995 - 2004	Southern California Society of Health-System Pharmacists (SCSHP) Co-chair, Education Committee (1996) Member, Nominations Committee (1996-8) Treasurer (1997) Member, House of Delegates (1997-99) Secretary (1998) President-elect (2000) Chair, Nominations Committee (2000) President (2001) Immediate Past President (2002)
1993 - Present	American College of Clinical Pharmacy (ACCP) Member, Publications Committee (1997-98) Member, Pharmacokinetic/Pharmacodynamic PRN (1997-2000) Member, Educational Affairs Committee (1998-2000) Member, Fellowship Review Committee (2001-2003) Member, Fellowship Awards Committee (2004-2005) Member, Research Affairs Committee (2006-2007) Member, Acute Care Task Force Committee (2010-2011) Secretary/Treasurer PK/PD/PG PRN (2014-2015)
1991 - 2004	California Society of Health-System Pharmacists (CSHP) Member, Continuing Education Committee, Focus '97 (1996-7) Member, Editorial Advisory Board (1997-99) Member, Editorial Advisory Board Internet subcommittee (1999 – 2000) Member, Practitioner Recognition Awards Committee (2001) Chair, Practitioner Recognition Awards Committee (2002) Member, Committee on Nominations (2003)
1990 – 2004	American Society of Health-System Pharmacists (ASHP) Member, Section of Clinical Specialists (1997-98) Member, Pharmacokinetics Network (1997-98) Network Facilitator on Pharmacokinetics (1998-99)

**Government**

2020- Present	FDA, Pharmaceutical Science and Clinical Pharmacology Advisory Committee (PSCP).
---------------	--

**HONORS AND AWARDS**

2018	Honorary Member, Phi Lambda Sigma.
2009	ACCP Annual Meeting Best Student Poster Presentation Student: Tim Bensman, B.S., Pharm.D. candidate

- 2009 AFPE Post-PharmD Fellowship Training Award –  
Fellow: Heather Owens, Pharm.D., MS
- 2008 ACCP Infectious Disease Fellowship Training Award  
Fellow: Heather Owens, Pharm.D., MS
- 2006 Fellow, American College of Clinical Pharmacy
- 2004 Residency Preceptor of the Year
- 2003 Career Development Research Award, American College of Clinical  
Pharmacy. P-glycoprotein and renal clearance of antibiotics in CF
- 2000 Practitioner Fellow, American Society of Health-System Pharmacists  
(FASHP)
- 1998 Practitioner Fellow, California Society of Health-System Pharmacists  
(FCSHP)
- 1998 Mini-sabbatical, April – June 1998. Sponsor: USC School of Pharmacy  
Training Site: Laboratory of Applied Pharmacokinetics, USC School of  
Medicine. Director, Roger Jelliffe, M.D.
- 1990-Present Rho Chi Pharmaceutical Honor Society

### **EDITORIAL REFEREE**

- 2013 – Present AJRCMM
- 2006 – Present Journal of Cystic Fibrosis
- 2004 – Present Journal of Antimicrobial Chemotherapy
- 2004 – Present Clinical Pharmacology and Therapeutics
- 2001 – Present Antimicrobial Agents and Chemotherapy
- 2001 – Present The American Journal of the Medical Sciences
- 1998 - Present Abstract Reviewer, American College of Clinical Pharmacy (ACCP)
- 1998 - Present Pharmacotherapy
- 1997 - Present Formulary
- 1996 - Present Annals of Pharmacotherapy

### **EDITORIALSHIPS**

Editor, Basic Clinical Pharmacokinetics 6<sup>th</sup> edition, 2018.

Section Editor, Pharmacokinetics/Pharmacodynamics in Remington's: The Science and  
Practice of Pharmacy, 21<sup>st</sup> edition. 2005

Section Editor, Textbook of Therapeutics, General Section. 8<sup>th</sup> Edition. 2005.

Editorial Advisory Board, Therapeutic Monitoring Section, Annals of Pharmacotherapy.

Section Editor, Therapeutic Drug Monitoring, Annals of Pharmacotherapy. 2010 - 2013

## RESEARCH SUPPORT

Principal Investigator - Comparative pharmacokinetics of a tablet and extemporaneous liquid formulation of lamotrigine. Glaxo-Wellcome. May 1998 - \$3,500.

Principal Investigator - Population pharmacokinetics of intravenous ciprofloxacin in adult cystic fibrosis patients. Bayer Pharmaceuticals. November 1998 - \$10,000.

Co-Investigator - Epidemiological study of cystic fibrosis (ESCF). Genentech. June 2000 – 2002 - \$4,000/year

Principal Investigator - Pharmacokinetics of ‘once-daily’ tobramycin in adult cystic fibrosis patients. Abbott Diagnostics. December 1998 - \$1,500.

Principal Investigator – Pharmacodynamics of continuous infusion cefepime in adult cystic fibrosis patients. Dura Pharmaceuticals. March 2000 - \$28,000

Co-Investigator – Evaluation of the absorption characteristics of oral linezolid during continuous enteral feedings. Pharmacia-Upjohn. December 2000 - \$50,000.

Co-Principal Investigator – In vitro evaluation of the immunomodulatory effects of celecoxib, azithromycin, and tacrolimus. Pharmacia Unrestricted Grant. August 2001 - \$10,000.

Principal Investigator – Impact of a formulary switch from ampicillin-sulbactam to piperacillin-tazobactam on patient outcomes in an orthopedic infectious diseases ward. Wyeth-Ayerst Unrestricted Grant. October 2001 - \$10,000

Principal Investigator – Bioavailability and intracellular pharmacokinetics of azithromycin in patients with cystic fibrosis. Webb Cystic Fibrosis Research Award. March 2002 - \$30,000.

Principal Investigator – Bactericidal activity of ampicillin-sulbactam, gatifloxacin and their combination against multi-drug resistant isolates of *Acinetobacter baumannii*. Bristol Myers Squibb. March 2002 - \$29,375

Principal Investigator – Contribution of renal P-gp to the enhanced clearance of antibiotics in patients with CF. American College of Clinical Pharmacy Career Development Award. June 2003 – July 2005, \$55,000.

Principal Investigator – Pharmacogenomics of *MDR1* in patients with CF. Webb Foundation CF Research Award. January 2005- \$27,500.

Principal Investigator – Impact of abnormal body composition on predictability of GFR in HIV. GSK. December 2006 – \$132,000. (Funding period Jan 2007 – April 2008).

Principal Investigator – Effect of pioglitazone on sputum biomarkers of inflammation and airway remodeling. Webb Foundation CF Research Award. January 2007 - \$38,000

Principal Investigator – Effect of doxycycline on sputum biomarkers of inflammation and airway remodeling. Webb Foundation CF Research Award. January 2008 - \$53,000

Principal Investigator – Establishment of an in-vitro model of CF airway inflammation/remodeling. Webb Foundation CF Research Award. January 2009 - \$27,000

Principal Investigator – Predictors of anti-inflammatory response to azithromycin in patients with cystic fibrosis. Webb Foundation CF Research Award. January 2010 – December 2010. \$45,600.

Principal Investigator – Evaluation of CXCR2 inhibition on airway inflammation in a murine model of CF. Webb Foundation CF Research Award. November 2010. \$53,000.

Principal Investigator - Pharmacodynamics of RTD-1, a Novel Peptide Inhibitor of TACE in an Experimental Model of Neutrophilic Airway Inflammation. NIH/NCRR SC CTSI Grant Number UL1 RR03986. September 2011. \$30,000.

Principal Investigator – Prospective observational study of biomarkers of aminoglycoside-induced acute kidney injury in patients with cystic fibrosis. Foundation for NIH. July 2012. \$334,000

Principal Investigator – Preclinical Pharmacokinetics of RTD-1. Webb Foundation CF Research Award. January 2012. \$20,000

Principal Investigator – Anti-inflammatory activity of Ang(1-7) in a murine model of chronic Pseudomonas airway infection. Tarix Pharmaceuticals. \$88,000

Co-Investigator - Novel macrocyclic peptides for in vivo blockade of arthritogenic proteases. Arthritis Foundation. January 2013. \$180,000.

Principal Investigator – Contribution of TACE to Airway Inflammation in CF. Webb Foundation CF Research Award. January 2013. \$30,000

Co-Investigator (PI-Selsted) - Molecular Aspects of Leukocyte Antimicrobial Peptides. 2R01AI022931-26A1 (Selsted) 06/01/2013-05/31/2017 NIH NIAID



Co-Investigator - Novel Therapeutic Approach for Multi-drug Resistant Mycobacteria (PI-Selsted) 07/01/2013 – 06/30/2014 Whittier Foundation

Principal Investigator - Mechanism of Macrocyclic Peptide Regulation of Pseudomonas-induced Pulmonary Inflammation. 12-1-14 to 11-31-16 Cystic Fibrosis Research Inc (CFRI).

Principal Investigator Targeting CF Infection and Inflammation with Aerosolized Theta-defensin 4-1-14 to 3-31-16. Cystic Fibrosis Foundation

Principal Investigator - Steady-state pharmacokinetics of tedizolid in plasma and sputum of patients with cystic fibrosis. Funded, Cubist Pharmaceuticals. 2015

Principal Investigator - Steady-state pharmacokinetics of ceftazidime/avibactam in plasma and sputum of patients with cystic fibrosis. Funded, Forest Labs. 2015

Principal Investigator – Impact of pharmacist interventions on clinical outcomes in patients with cystic fibrosis. Funded, Gilead. 2016

Co- Principal Investigator. Design and evaluation of cyclotide-based antimicrobial microproteins as therapeutic leads. USC School of Pharmacy Interdisciplinary Research Award. 2018-2020.

Principal Investigator. Pharmacokinetics of omadacycline in CF. Paratek Pharmaceuticals. November 2020.

Principal Investigator. Impact of Rifabutin on the Pharmacokinetics of Elexacaftor-Tezacaftor-Ivacaftor. Cystic Fibrosis Foundation. September 2021.

Principal Investigator. *In vitro* and *in vivo* activity of imipenem-relabactam alone and in combination against CF isolates of *Mycobacterium abscessus*. Merck. November 2021.

## BIBLIOGRAPHY

### *Peer Reviewed Journals*

Park A Young J., Tran DQ, Schaal JB, Wang M, Selsted ME, **Beringer PM**. Preclinical pharmacokinetics and safety of intravenous RTD-1. *Antimicrob. Agents Chemother* 2022;66(3)

Dughbaj MA, Jayne JG, Park AY, Bensman TJ, Algorri M, Ouellette AJ, Selsted ME, **Beringer PM**. Anti-Inflammatory Effects of RTD-1 in a Murine Model of Chronic *Pseudomonas aeruginosa* Lung Infection: Inhibition of NF- $\kappa$ B, Inflammasome Gene Expression, and Pro-IL-1 $\beta$  Biosynthesis. *Antibiotics* 2021, 10(9), 1043; <https://doi.org/10.3390/antibiotics10091043>.

[Chaudhuri D](#), [Ganesan R](#), Vogelaar A, Dughbaj MA, **Beringer PM**, Camarero JA. Chemical Synthesis of a Potent Antimicrobial Peptide Murepavadin Using a Tandem Native Chemical Ligation/Desulfurization Reaction. *J Org Chem*. 2021 Oct 12. PMID: 34641669.

Ganesan R, Dughbaj MA, Ramirez L, Beringer S, Aboye TL, Shekhtman A, **Beringer PM**, Camarero JA. Engineered Cyclotides with Potent Broad in Vitro and in Vivo Antimicrobial Activity. *Chemistry*. 2021 Jun 22. PMID: 34159664.

Wang W, He H, Marín-Ramos N, Zeng S, Swenson S, Cho H, Fu J, **Beringer PM**, Neman J, Chen L, Schönthal AH, Chen TC. Enhanced brain delivery and therapeutic activity of trastuzumab after blood-brain barrier opening by NEO100 in mouse models of brain-metastatic breast cancer. *Neuro Oncol*. 2021 Feb 28;noab041. doi: 10.1093/neuonc/noab041.

Basso V, Tran DQ, Schaal JB, Tran P, Eriguchi Y, Ngole D, Cabebe AE, Park AY, **Beringer PM**, Ouellette AJ, Selsted ME. Rhesus Theta Defensin 1 Promotes Long Term Survival in Systemic Candidiasis by Host Directed Mechanisms. *Sci Rep* 2019;9:16905.

Avedissian SN, Rhodes N, Ng T, Rao AP, **Beringer PM**. The Potential for QT Interval Prolongation with Chronic Azithromycin Therapy in Adult Cystic Fibrosis Patients. *Pharmacotherapy* 2019;39:718-23.

Park AY, Wang J, Jayne J, Fukushima L, Rao AP, D'Argenio DZ, and **Beringer PM**. Pharmacokinetics of Tedizolid in Plasma and Sputum of Adults with Cystic Fibrosis. *Antimicrob. Agents Chemother*. 2018;62:e00550-18

Jayne, JG, Bensman TJ, Schaal JB, Park AY, Kimura E, Tran D, Selsted ME, **Beringer PM**. Rhesus theta defensin-1 attenuates endotoxin-induced acute lung injury by inhibiting proinflammatory cytokines and neutrophil recruitment. *Am J Resp Cell Mol Biol* 2017.

Schaal JB, Tran D, Subramanian A, Patel R, Laragione T, Roberts KD, Trinh K, Tongaonkar P, Tran P, Minond D, Fields GB, **Beringer PM**, Ouellette AJ, Gulko PS, Selsted ME. Suppression and Resolution of Autoimmune Arthritis by Immunomodulatory  $\theta$ -Defensins. *PLOS ONE* 2017.

Bensman TJ, Wang J, Jayne J, Fukushima L, Rao AP, D'Argenio DZ, and **Beringer PM**. Pharmacokinetic-Pharmacodynamic Target Attainment Analyses to Determine Optimal Dosing of Ceftazidime-Avibactam for the Treatment of Acute Pulmonary Exacerbations in Cystic Fibrosis. *Antimicrob. Agents Chemother*. 2017; doi:10.1128/AAC.00988-17

Bensman TJ, Jayne J, Sun M, Kimura E, Meinert J, Wang JC, Schaal JB, Tran D, Rao AP, Akbari O, Selsted ME, **Beringer PM**. Efficacy of Rhesus Theta ( $\theta$ )-Defensin-1 in Experimental Models of *Pseudomonas aeruginosa* Lung Infection and Inflammation. *Antimicrobial Agents Chemother* 2017;8:61:e00154-17.

**Beringer PM**, Bensman TJ, Ho H, Agnello M, Denovel N, Nguyen A, Wong-Beringer A, She R, Tran DQ, Moskowitz SM, Selsted ME. Rhesus theta-defensin-1 (RTD-1) exhibits *in vitro* and *in vivo* activity against cystic fibrosis strains of *Pseudomonas aeruginosa*. J Antimicrob Chemother 2016;71:181-188. PMID: 26433781

Ha H, Debnath B, Odde S, Bensman T, Ho H, **Beringer PM**, and Neamati N. Discovery of Novel CXCR2 Inhibitors Using Ligand-Based Pharmacophore Models. J Chem Information Modeling. 2015; 55(8):1720-38. PMID: 26153616

Neamati N, Ha H, Bensman T, Ho H, **Beringer PM**. A novel phenylcyclohex-1-enecarbothioamide-based compound inhibits CXCL-8-mediated chemotaxis through selective regulation of CXCR2-mediated signaling. Br J Pharmacol. 2014;171:1551-65.

Lambros MP, **Beringer PM**, Wong-Beringer A. Nebulizer choice affects the airway targeting of amphotericin B lipid complex aerosols. J Pharm Technol 2013;29:199-204.

Bensman T, Nguyen A, Rao AP, **Beringer PM**. Doxycycline exhibits anti-inflammatory activity in CF bronchial epithelial cells. Pulm Pharmacol Ther. 2012 Oct;25(5):377-82. PMID: 22771903

Haas C, Eckel S, Arif S, **Beringer PM**, et al. Acute Care Clinical Pharmacy Practice Models: Unit- vs. Service-Based Models. Pharmacotherapy. 2012 Feb;32(2):e35-44. PMID: 22392430.

**Beringer PM**, Owens H, Nguyen A, Benitez D, Rao A, D'Argenio DZ. Pharmacokinetics of doxycycline in adults with cystic fibrosis. Antimicrob Agents Chemother. 2012 Jan;56(1):70-4. PMID: 22024822

Minejima E, Choi J, **Beringer P**, Lou M, Tse E, Wong-Beringer A. Applying new diagnostic criteria for acute kidney injury to facilitate early identification of nephrotoxicity in vancomycin-treated patients. Antimicrob Agents Chemother. 2011 Jul;55(7):3278-83.

Wong-Beringer, A., Joo J, Tse E, **Beringer P**. Vancomycin-associated nephrotoxicity: a critical appraisal of risk with high-dose therapy. Int J Antimicrob Agents 2011;37:95-101

Dowling TC, Murphy JE, Kalus JS, Nkansah NT, Chappell JC, Wiederhold NP, **Beringer P**, Crews KR, Grabinski JL, Evens RP, Leff R. Recommended education for pharmacists as competitive clinical scientists. Pharmacotherapy 2009;29:236-244. PMID: 19170592

**Beringer PM**, Hidayat L, Heed A, Zheng L, Owens H, Benitez D, Rao AP. GFR estimates using cystatin C are superior to serum creatinine in adult patients with cystic fibrosis. J Cyst Fibros. 2009 Jan;8(1):19-25. PMID: 18799365

**Beringer PM**, Kriengkauykiat J, Zhang X, Hidayat L, Liu S, Louie S, Synold T, Burckart GJ, Rao PA, Shapiro B, Gill M. Lack of effect of P-glycoprotein inhibition on

renal clearance of dicloxacillin in patients with cystic fibrosis. *Pharmacotherapy*. 2008 Jul;28(7):883-94. PMID: 18576903

Liu S, **Beringer PM**, Hidayat L, Rao AP, Louie S, Burckart GJ, Shapiro B. Probenecid, but not cystic fibrosis, alters the total and renal clearance of fexofenadine. *J Clin Pharmacol*. 2008 Aug;48(8):957-65. PMID: 18511651

Han E, **Beringer PM**, Sprauten PF, Louie S, Rao P, Shapiro B, and Gill MA. Pilot study of continuous infusion cefepime in adult patients with cystic fibrosis. *J Antimicrob Chemother* 2006;57:1017-1019.

**Beringer PM**, Huynh K, Krienkauykiat J, Bi L, Hoem N, Han E, Louie S, Rao A, Shapiro BJ, Gill M. Bioavailability and intracellular pharmacokinetics of azithromycin in patients with cystic fibrosis. *Antimicrob Agents Chemother* 2005;49:5013-5017.

**Beringer PM**, Nguyen M, Hoem N, Louie S, Gill M, Gurevitch M, Wong-Beringer A. Population pharmacokinetic analysis to evaluate the impact of continuous enteral feedings on the bioavailability of linezolid in hospitalized patients. *Antimicrob Agents Chemother* 2005;49:3676-3681.

Wong-Beringer A, Lambros M, **Beringer PM**, Johnson DL. Suitability of inhaled caspofungin for prevention of pulmonary aspergillosis: physicochemical profiling and nebulizer choice. *Chest* 2005;128:3711-3716.

Garcia AA, Pujari M, Jeffers S, Iqbal S, Lenz HJ, **Beringer P**, Louie SG. Phase I clinical and pharmacokinetic trial of docetaxel and irinotecan administered on a weekly schedule. *Cancer Chemother Pharmacol* 2005;56:75-82.

**Beringer PM**, Slaughter RL. Transporters and their impact on drug disposition. *Ann Pharmacother* 2005;39:1097-1108.

**Beringer PM**, Han E, Louie SG, Gill MA, Shapiro BJ. Pharmacokinetics of ibuprofen in children with cystic fibrosis. *Clin Pharmacokinet* 2004;43:145-56.

Swadron SP, Rudis MI, Azimian K, **Beringer P**, Fort D, Orlinsky M. A Comparison of Phenytoin-loading Techniques in the Emergency Department. *Acad Emerg Med* 2004; 11(3): 244-252

Dattilo CV, **Beringer PM**, Gill MA. The management and treatment of osteomyelitis. *California Pharmacist* 2003:55-65.

Sprauten P, **Beringer PM**, Louie SG, Gill MA. Stability and antibacterial activity of cefepime during continuous infusion administration. *Antimicrob Agents Chemother* 2003;47:1991-94.

Aminimanizani A, **Beringer PM**, Tsang L, Shapiro B, Jelliffe R. Pharmacokinetics of once-daily tobramycin administration in adult patients with cystic fibrosis. *J Antimicrob Chemother* 2002;50:553-9.

Grant T, **Beringer PM**, Nguyen T, Gill MA. Cystic fibrosis: pathophysiology and pharmacological management. *US Pharmacist* 2002(July) HS44-62.

**Beringer PM**, Aminimanizani A, Scott C, Synold T. Development of population pharmacokinetic models and optimal sampling times for ibuprofen in children with cystic fibrosis. *Ther Drug Monitor* 2002;24:315-21.

Montgomery MJ, **Beringer PM**, Aminimanizani A, Louie SG, Shapiro B, Jelliffe R, Gill MA. Population Pharmacokinetics and use of Monte Carlo simulation to determine the optimal dose of ciprofloxacin in adult patients with cystic fibrosis. *Antimicrob Agents Chemother* 2001;45:3468-73.

Aminimanizani A, **Beringer PM**, Jelliffe R. Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone agents. *Clin Pharmacokinet* 2001;40:169-87.

Montgomery MJ, **Beringer PM**, Louie SG, Gill MA. Estimation of creatinine clearance in patients with metastatic ovarian cancer receiving peritoneal chemotherapy. *Ther Drug Monitor* 2000;22:695-700.

**Beringer PM**, Vinks A, Jelliffe R, Shapiro B. Pharmacokinetics of tobramycin in adults with cystic fibrosis: Implications for once-daily administration. *Antimicrob Agents Chemother* 2000;44:809-813.

**Beringer PM**, Wong-Beringer A, Rho JP. Predictive performance of a vancomycin-aminoglycoside population model. *Ann Pharmacother* 1998;32:176-81.

**Beringer PM**, Vinks A, Jelliffe R. Pharmacokinetics of once-daily amikacin dosing in patients with cystic fibrosis. [letter] *J Antimicrob Chemother* 1998;41:142-44.

**Beringer PM**, Wong-Beringer A, Rho JP. Economic aspects of antibacterial adverse effects. *Pharmacoeconomics* 1998;13:35-49.

Wong-Beringer A, **Beringer PM**, Lovett MA. Successful treatment of meningitis due to multi-drug resistant *Pseudomonas aeruginosa* with high-dose ciprofloxacin therapy. *Clin Infect Dis* 1997;25:936-7.

**Beringer PM**, Rho JP. Comparing the newest fluoroquinolones: Levofloxacin and sparfloxacin *Formulary* 1997;32:926-43.

**Beringer PM**, Rho JP. Is routine measurement of free phenytoin concentrations rational? [letter] *Therapeutic Drug Monitoring*. 1995;17:381-2.

*Non Peer Reviewed Journals*

Nguyen T, Louie SG, **Beringer PM**, Gill MA. Potential role of macrolide antibiotics in the management of cystic fibrosis lung disease. *Curr Opinion Pulm Med* 2002;8:521-8.

**Beringer PM**. The clinical use of colistin in patients with cystic fibrosis. *Curr Opinion Pulm Med* 2001;7:434-40.

**Beringer PM**. Unusual microbiological flora in cystic fibrosis lungs: identification and therapy. *Curr Opinion Pulm Med* 2000;6:545-550.

**Beringer PM**. New Approaches to optimizing antimicrobial therapy in patients with cystic fibrosis. *Curr Opinion Pulm Med* 1999;5:371-77.

**Beringer PM**. Clinical Pharmacokinetics in the New Millenium. *Network News Bytes*, American Society of Health-System Pharmacists 1999;5:7.

**Beringer PM**. Management of pulmonary infections in cystic fibrosis *Pharmaguide to Clinical Medicine* 1998;11:1-6.

**Beringer PM**, Rho JP. Antibiotic dosing in patients receiving peritoneal dialysis. *Antibiotics for the Clinician* 1997;1:12-15.

**BOOK CHAPTERS:**

**Beringer PM**, Condren M. Cystic Fibrosis. In: Koda-Kimble M, Young L, eds. *Applied Therapeutics: The Clinical Use of Drugs*. Lippincott Williams & Wilkins. 12th edition 2021.

Han E, **Beringer PM**. Aminoglycosides In: Winter M, ed. *Basic Pharmacokinetics*. Lippincott Williams & Wilkins. 6th edition 2018.

Bensman T, **Beringer PM**. Vancomycin In: Winter M, ed. *Basic Pharmacokinetics*. Lippincott Williams & Wilkins. 6th edition 2018.

**Beringer PM**, Condren M. Cystic Fibrosis. In: Koda-Kimble M, Young L, eds. *Applied Therapeutics: The Clinical Use of Drugs*. Lippincott Williams & Wilkins. 11th edition 2016.

**Beringer PM**. Cystic Fibrosis in RxPrep 2015, 2016.

**Beringer PM**. Pharmacokinetics in RxPrep 2015, 2016.

**Beringer PM** Winter, ME. Clinical Pharmacokinetics In: Remingtons: The Science and Practice of Pharmacy. Lippincott Williams & Wilkins. 22nd edition 2012.

**Beringer PM**, Condren M. Cystic Fibrosis. In: Koda-Kimble M, Young L, eds. *Applied Therapeutics: The Clinical Use of Drugs*. Lippincott Williams & Wilkins. 10th edition 2012.

Middleton R, **Beringer PM**. Anaphylaxis and Systemic Drug Allergies. In: Koda-Kimble M, Young L, eds. *Applied Therapeutics: The Clinical Use of Drugs*. Lippincott Williams & Wilkins. 10th edition 2012.

**Beringer PM**. Aminoglycosides In: Winter M, ed. Basic Pharmacokinetics. Lippincott Williams & Wilkins. 5th edition 2009.

Middleton R, **Beringer PM**. Anaphylaxis and Systemic Drug Allergies. In: Koda-Kimble M, Young L, eds. *Applied Therapeutics: The Clinical Use of Drugs*. Lippincott Williams & Wilkins. 9th edition 2008.

**Beringer PM**, Condren M. Cystic Fibrosis. In: PSAP V Chronic Illnesses/Pediatrics. 2006.

**Beringer PM**. Han E. Cystic Fibrosis. In: Herfindal ET, Gourley R. eds. *Textbook of Therapeutics: Drug and Disease Management* 8th ed. 2006.

**Beringer PM** Winter, ME. Clinical Pharmacokinetics In: Remingtons: The Science and Practice of Pharmacy. Lippincott Williams & Wilkins. 21st edition 2005.

Middleton R, **Beringer PM**. Anaphylaxis and Systemic Drug Allergies. In: Koda-Kimble M, Young L, eds. *Applied Therapeutics: The Clinical Use of Drugs*. Lippincott Williams & Wilkins. 8th edition 2004.

**Beringer PM**. Aminoglycosides In: Winter M, ed. Basic Pharmacokinetics. Lippincott Williams & Wilkins. 4th edition 2004.

**Beringer PM**, Middleton R. Anaphylaxis and Systemic Drug Allergies. In: Koda-Kimble M, Young L, eds. *Applied Therapeutics: The Clinical Use of Drugs*. Lippincott Williams & Wilkins. 7th edition 2001.

**Beringer PM**. Cystic Fibrosis. In: Herfindal ET, Gourley R. eds. *Textbook of Therapeutics: Drug and Disease Management* 7th ed. 2000

**Beringer PM**. Renal Disease Cases In: Schroeder D. ed. *Workbook for Clinical Pharmacy and Therapeutics* 6th ed. 1996.

**Beringer PM**, Middleton R. Anaphylaxis and Systemic Drug Allergies. In: Koda-Kimble M, Young L, eds. *Applied Therapeutics: The Clinical Use of Drugs*. Vancouver: Applied Therapeutics Inc. 6th edition 1995.

**Beringer PM.** Renal Disease Cases In: Herfindal ET, Gourley R, Hart L. eds. *Workbook for Clinical Pharmacy and Therapeutics* 5th ed. 1992.

## PRESENTATIONS/ABSTRACTS

Beringer PM. Therapeutic Potential of RTD-1 for Treatment of Airway Infection/Inflammation in CF,” 30th Annual CFRI Research and Family Education Conference, in San Francisco, CA, July 30, 2017.

Bensman TJ, Wang J, D’Argenio DZ, and Beringer PM. Pharmacokinetic-Pharmacodynamic Target Attainment Analysis of Ceftazidime-Avibactam in CF. ASM Microbe, New Orleans, LA, June 1-5, 2017.

Jayne J, Bensman T, Wang J, Trinh K, Rao A and **Beringer P.** Mechanism of Action of the Immune Modulating Peptide Rhesus Theta-Defensin 1 (RTD-1).[Poster] North American Cystic Fibrosis Conference, Orlando, FL, October 27-29, 2016.

Wang J, Lester M, Benitez D, Rao AP, Beringer PM. Use of In-Clinic Challenge Dosing to Assess Safety and Tolerability of Lumacaftor/Ivacaftor (L/I). North American Cystic Fibrosis Conference, Orlando, FL, October 27-29, 2016. [poster and platform presentations].

Bensman T, Kimura E, Sun M, Meinert J, Jayne J, Schaal J, Tran D, Selsted M, **Beringer PM.** Pharmacokinetics, efficacy, and safety of RTD-1 in a murine model of chronic *Pseudomonas aeruginosa* airway infection. 2015 North American CF Conference. Phoenix, AZ November 2015.

Jayne J, Bensman T, Habib S, Trinh K, Wang J, **Beringer PM.** RTD-1 as a potential anti-inflammatory therapy for CF lung disease. Rocky Mountain Bioinformatics Conference, Aspen, CO December 2015.

**Beringer PM.** Antibacterial activity of theta defensin, (RTD-1), against clinical isolates of *Pseudomonas aeruginosa*. European Cystic Fibrosis Congress, Gothenburg Sweden, June 2014. Platform presentation.

Bensman T, Rodgers K, **Beringer PM.** Anti-inflammatory activity of Ang (1-7) in a murine model of chronic *Pseudomonas aeruginosa* airway infection. 2014 North American CF Conference. Atlanta, GE November 2014.

**Beringer PM.** Use of novel biomarkers to reduce acute kidney injury due to aminoglycosides in CF. 2013 North American CF Conference. Platform presentation.



Ho H, T. Bensman, H. Ha, N. Neamati, P. Beringer. *Evaluation of Novel CXCR2 Antagonists to Combat Neutrophilic Airway Inflammation*. 2012 NACFC Annual Meeting: Pediatric Pulmonology Supplemental, 2012.

T. Bensman, I. de Veth, D. Benitez, A. Rao, D. D'Argenio, **P. Beringer**. *Pharmacokinetics and Ex-Vivo anti-inflammatory effects of Azithromycin*. 2012 NACFC Annual Meeting: Pediatric Pulmonology Supplemental, 2012.

T. Bensman, D. Tran, J. Schaal, M. Selsted, **P. Beringer**. *Therapeutic Evaluation of a Novel Rhesus Theta Defensin in Neutrophilic Airway Disease*. 2012 NACFC Annual Meeting: Pediatric Pulmonology Supplemental, 2012.

T. Bensman, A. Nguyen, H. Ho, A. Messali, D. Benitez, A. Rao, **P. Beringer**. *Peripheral TH1/TH2 Cytokine Response in Cystic Fibrosis*. 2011 NACFC Annual Meeting: Pediatric Pulmonology Supplemental, 2011.

T. Bensman, A. Nguyen, A. Rao, **P. Beringer**. *Immunomodulatory Effects of Doxycycline in Cystic Fibrosis Airway Epithelial Cells*. 2010 NACFC Annual Meeting: Pediatric Pulmonology Supplemental, 2010.

Tim Bensman, Adupa P. Rao, **Paul Beringer**. Immunomodulatory effects of doxycycline in cystic fibrosis airway epithelial cells. American College of Clinical Pharmacy Annual Meeting, Anaheim, October 2009. Best student poster award.

Heather Owens, Adupa P. Rao, **Paul Beringer**. Effect of doxycycline on sputum biomarkers of inflammation in patients with cystic fibrosis. American College of Clinical Pharmacy Annual Meeting, Anaheim, October 2009.

Nicholas Mordwinkin, Purush Rao, Jeonghoon Anh, **Paul Beringer**. Effect of key pharmacological therapies on pulmonary function in adult patients with cystic fibrosis. American Society of Health System Pharmacists Annual Meeting, Anaheim, December 2006.

**Beringer, PM**; Hidayat L.; Rao, A.P.; Liu S.; Shapiro, B.J Controlled evaluation of cystatin C as a marker of glomerular filtration rate in CF. North American Cystic Fibrosis Conference, Denver, November 2006.

**Beringer PM**, Kriengkauykiat J, Zhang X, Hidayat L, Bi L, Louie S, Synold T, Gill M, Burckart G, Rao P, Shapiro B. P-glycoprotein and renal clearance of antibiotics in patients with cystic fibrosis. Career Development Research Award. American College of Clinical Pharmacy Annual Meeting, San Francisco, October 2005.

Bi L, **Beringer PM**, Huynh K, Hoem N, Louie S, Gill M. Controlled pharmacokinetic study of bioavailability and intracellular PK of azithromycin in patients with cystic fibrosis. ASCPT Annual Meeting, Orlando, March 2005.

**Beringer PM**, Krienkauykiat J, Louie S, Gill M, Woo M, Rao A, Shapiro B. Bioavailability of azithromycin in patients with cystic fibrosis. North American Cystic Fibrosis Conference, St. Louis, October 2004.

Han E, **Beringer P**, Louie S, Cosep M, Gill M. Serum bactericidal titers from healthy volunteers of gatifloxacin and ampicillin-sulbactam alone and in combination against *Acinetobacter baumannii*. ASHP Midyear Clinical Meeting. New Orleans, LA. December, 2003.

**Beringer P**, Shapiro B, Han E, Louie S, Gill M, Rao A. Pharmacodynamics of continuous infusion cefepime in adult cystic fibrosis patients. Seventeenth North American Cystic Fibrosis Conference. Anaheim, California. October 2003. (Abstract 330).

Sprauten P, **Beringer PM**, Louie SG, Gill MA. Stability and antibacterial activity of cefepime during continuous infusion administration. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA. September 2002.

Montgomery M, **Beringer PM**, Aminimanizani A, Louie S, Citron D, Shapiro B, and Gill M. Pharmacokinetics of ciprofloxacin in adult patients with cystic fibrosis. *ACCP Spring Forum*. Salt Lake City, UT. April 2001.

Montgomery M, **Beringer PM**, Louie S, Shapiro B, Gill M. Are we overdosing patients receiving concurrent intravenous and inhaled tobramycin? *ACCP Spring Forum*. Salt Lake City, UT April 2001.

Aminimanizani A, **Beringer PM**. Pharmacokinetics of once-daily tobramycin in an adult cystic fibrosis population. ASHP Midyear Clinical Meeting. Orlando, Florida. December 1999 and *Fourteenth Annual North American Cystic Fibrosis Conference*. Baltimore, Maryland. November, 2000.

Aminimanizani A, Scott C, Synold T, **Beringer PM**. Development of a population pharmacokinetic model and optimal sampling times for ibuprofen in patients with cystic fibrosis. *ACCP Spring Forum*. Monterey, CA. April 2000.

**Runner-up, best student/resident/fellow competition-ACCP**

**Beringer PM**, Vinks, S, Jelliffe RW, Shapiro BJ. Evaluation of the genotypic variation in aminoglycoside pharmacokinetics in an adult cystic fibrosis population. *Thirteenth Annual North American Cystic Fibrosis Conference*. Seattle, Washington. October, 1999 [abstract 342].

Montgomery M., **Beringer PM**, Gill MA, Louie S. Estimation of Creatinine Clearance in Patients with Ovarian Cancer. *19th Annual Western States Conference for Pharmacy Residents and Preceptors*. Pacific Grove, California. 1999 and *ACCP Annual Meeting*. Kansas City, Missouri. October 1999 [abstract 128].

Resident project-of-the-year award, USC School of Pharmacy, June, 1999.

Salamunovich S, **Beringer PM**, Chin A. Evaluation of vancomycin dosing and monitoring strategies in hematology/oncology patients. *19th Annual Western States Conference for Pharmacy Residents and Preceptors*. Pacific Grove, California. 1999 and *ACCP Annual Meeting*. Kansas City, Missouri. October 1999 [abstract 158].

**Beringer PM**, Wong-Beringer A, Rho JP. Predictive performance of a vancomycin-aminoglycoside population model. *1996 Annual Meeting American College of Clinical Pharmacy*. Nashville, Tennessee. August 4-7, 1996.

**Beringer PM**, Ulrich R, Rho JP. Evaluation of Therapeutic Drug Concentration Scheduling and Reporting. *30th Annual ASHP Midyear Clinical Meeting*. Las Vegas, Nevada. December 1995.

**Beringer PM**, Winter ME. An integrated package of pharmacokinetic programs for a hand-held pocket calculator. *27th Annual ASHP Midyear Clinical Meeting*. Orlando, Florida. December 1992.

**Beringer PM**, Winter ME. Analysis of serum drug concentration ordering at UCSF. *12th Annual Western States Conference for Pharmacy Residents and Preceptors*. Pacific Grove, California. 1992.

**Beringer PM**, Winter ME. Influence of intensive care stay on creatinine excretion. *11th Annual Western States Conference for Pharmacy Residents and Preceptors*. Pacific Grove, California. 1991.

## INVITED LECTURES/SEMINARS

AUC vs trough level monitoring for vancomycin therapy. North American Cystic Fibrosis Conference. Orlando, FL. November 2016.

Novel biomarkers for early detection of aminoglycoside-induced acute kidney injury in CF. North American CF Conference. November 2013. Salt Lake City, UT.  
Management of antibiotic drug allergies in patients with CF. Pulmonary and Critical Care Medicine. USC, October 2013.

Choosing the right antibiotics for treatment of acute pulmonary exacerbations. Advanced practice nursing forum. North American Cystic Fibrosis Conference. November 2012. Orlando, CA.

Evidence Based Medication Management of Patients with Allergic Asthma. 1 hour ACPE.  
HealthNet, Woodland Hills. 2-25-09  
Medical Los Angeles, 3-11-09

Disease Management Strategies to Improve Respiratory Outcomes in Patients with Cystic Fibrosis.

MedImpact, San Diego. 1/13/2005

SFSHP, Encino. 6/8/2005

CEPA, Los Angeles. 7/20/2005

CEPA, Newport Beach. 8/31/2005

CSHP Annual, Anaheim. 10/21/2005

PCN, Sacramento. 11/1/2005.

Current drug therapy issues in patients with cystic fibrosis.

Wellpoint. 1 CEU ACPE. 6/2004

Rx Solutions. 1 CEU ACPE 9/2004

Tips for securing grant funding. ACCP Annual Meeting. 10/26/2004

Role of azithromycin in patients with CF. Laboratory of Applied pharmacokinetics workshop. 1 hour. 7/2004

Pharmacokinetics of linezolid during continuous enteral feeding in hospitalized patients. Laboratory of Applied pharmacokinetics workshop. 1 hour. 7/2004

PK/PD optimization of antibiotic therapy in patients with cystic fibrosis. School of Pharmacy, University of Oslo, Norway. October 2002.

Immune modulating effects of macrolides: Potential role in cystic fibrosis. Infectious disease grand rounds. LAC+USC Medical Center, September 2002.

Role of aerosolized antibiotics in the treatment of pulmonary infections. Medical center grand rounds:

USC Department of Pulmonary and Critical Care Medicine, February 2002

Womens and Childrens Hospital LAC+USC, April 2001

Pediatric Medicine, Kaiser Panorama City, May 2001

UCSD Department of Pharmacy, December 2001

UCLA Department of Pulmonary and Critical Care Medicine, December 2001

Childrens Hospital, Los Angeles. December 2000

Once-daily aminoglycoside dosing in patients with cystic fibrosis. North American Cystic Fibrosis Conference. November 2001.

Optimizing aerosolized antimicrobial therapy in patients with cystic fibrosis: Role of the Pharmacist. ASHP Midyear Clinical Meeting. December 2000.

Pharmacokinetics of ciprofloxacin in adult cystic fibrosis patients. Laboratory for Applied Pharmacokinetics workshop. USC Health Sciences Campus, Los Angeles, CA November 2000.

Pharmacokinetic considerations in the elderly. Geriatric certification preparatory course. UCLA School of Medicine. September 2000. [2 ACPE credits].

Therapeutic drug monitoring in the new millenium. Memorial Medical Center, Modesto, CA. April 2000.

Development of a population pharmacokinetic model and optimal sampling times for ibuprofen in children with cystic fibrosis. Laboratory for Applied Pharmacokinetics Workshop, USC Health Sciences Campus, Los Angeles, CA. March 2000

Management of antibacterial resistance in cystic fibrosis. Patient Care Day. USC Cystic Fibrosis Center. Los Angeles, California, March 1999.

Pharmacokinetics of HBIG in Liver Transplant Recipients with Chronic Hepatitis B. Liver Service Grand Rounds. USCUIH. March 1998

Pharmacological Management of Cystic Fibrosis Lung Disease. Respiratory Therapy Continuing Education Seminar. USCUIH. December 1997, February 1998.

Dosage Adjustment in Patients with Changing Renal Function: Chasing a Moving Target? Clinical Pearls Presentation. ASHP Midyear Clinical Meeting. Atlanta, Georgia. December 1997.

Population PK/PD Modeling and New Methods for Model-Based, Goal-Oriented, Individualized Drug Therapy. Pre-ACCP Workshop. Phoenix, Arizona. November 1997.

Optimizing Antimicrobial Therapy: The Role of Pharmacokinetics/Pharmacodynamics. Postgraduate Education Program. University of Southern California School of Pharmacy. Las Vegas, Nevada. [1 ACPE credit] March 1996

Diabetes And Patient Education. Complications Of Diabetes Mellitus. California Pharmacists Association. Burlingame, California. [1 ACPE credit] March 1993.  
Quinolones In The Treatment Of Chronic Osteomyelitis. Pharmacy grand rounds. University of California San Francisco. San Francisco, California. March 1991